Table S1. Treatment and study disposition.

Status	All patients with *RET* fusion-positive NSCLC and intracranial metastases (N=80)
Starting selpercatinib dose, n (%)	
20 mg BID	1 (1.3)
40 mg BID	4 (5.0)
60 mg BID	1 (1.3)
80 mg BID	2 (2.5)
120 mg BID	6 (7.5)
160 mg BID [a]	65 (81.3)
240 mg BID	1 (1.3)
Subjects who received at least one dose of 160 mg BID, n (%) [a]	76 (95.0)
Starting dose of 160 mg BID	65 (81.3)
Intra-patient dose escalated to 160 mg BID	10 (12.5)
Dose reduced to 160 mg BID	1 (1.3)
Treatment continued post-progression, n (%) [b]	29 (36.3)
Treatment status, n (%)	
Discontinued	34 (42.5)
Continuing	46 (57.5)
Reason treatment discontinued, n (%)	
Progressive disease [b]	23 (28.8)
Adverse event	6 (7.5)
Withdrawal of consent	2 (2.5)
Death	3 (3.8)
Study status, n (%)	
Discontinued	23 (28.8)
Continuing	57 (71.3)
Reason study discontinued, n (%)	
Withdrawal of consent	8 (10.0)
Death	15 (18.8)
Time on treatment (months)	
N	80
Mean	10.9
Standard deviation	6.3
Median	10.5
Minimum	0.2
Maximum	27.8
Time on study (months)	
N	80
Mean	11.6
Standard deviation	6.2
Median	11.1
Minimum	0.4
Maximum	27.8

[a] 160 mg BID is the recommended phase 2 dose.
[b] Any progressive disease, not limited to intracranial metastases progression.